Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Director Adam Koppel sold 1,500,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $24.68, for a total transaction of $37,020,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
NASDAQ DRNA traded down $0.21 on Monday, hitting $26.42. The stock had a trading volume of 4,487 shares, compared to its average volume of 1,482,621. Dicerna Pharmaceuticals Inc has a 52-week low of $9.31 and a 52-week high of $27.40. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -22.08 and a beta of 2.38. The firm has a 50-day moving average of $19.86 and a 200-day moving average of $15.59.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.15). Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. The firm had revenue of $8.04 million during the quarter, compared to analysts’ expectations of $11.70 million. Equities research analysts expect that Dicerna Pharmaceuticals Inc will post -0.56 EPS for the current year.
A number of analysts recently commented on the stock. SunTrust Banks upped their price target on shares of Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, November 18th. ValuEngine cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Leerink Swann restated an “outperform” rating and set a $30.00 price target (up from $26.00) on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target (up from $22.00) on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 19th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $27.38.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Featured Article: Initial Coin Offerings entail a high degree of risk
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.